The Irritable bowel syndrome is a gastrointestinal disorder of gut that may be acknowledged by the colon muscle contraction. It majorly distresses the large intestine. In addition, it is linked with the malfunction of the bowel, and majorly happens in geriatric populace. Diarrhea, constipation, alteration & uneasiness in bowel function, bloating, and abdominal pain are some of the mutual symptoms of the irritable bowel syndrome.
Endoscopy and blood test are customarily performed to perceive this irritable bowel syndrome. Irritable bowel syndrome is categorized into three forms such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Handling of irritable bowel syndrome involves the proper medicines, variation in diet, stress relief, and counseling. Medicines utilized in the treatment of irritable bowel syndrome involve rifaximin, eluxadoline, lubiprostone, linaclotide, and several others.
According to the report analysis, ‘Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026’states that in the irritable bowel syndrome treatment market there are innumerable entities which presently working more proficiently for leading the fastest market growth and registering the great value of market share around the globe during the coming future while analyzing and studying the strategies of the competitors, developing the specifications of the technologies, advancing the profits and applications of such, employing the effective strategies of profit making, spreading the awareness related to the irritable bowel syndrome treatment, delivering the better consumer satisfaction, decreasing the associated price and employing the young work force includes Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd and numerous others.
Although, the irritable bowel syndrome treatment market was worth at USD 1,071 million in 2018, and is estimated to reach at USD 2,012 million by 2026, dominating a CAGR of 8.2% from 2019 to 2026. Whereas, effective increase in the prevalence of gastrointestinal diseases and disorders such as modification of the bowel habit, abdominal pain, implementation of sedentary lifestyle, augment in level of stress, and unhealthy diet are the foremost factors that influence the growth of the irritable bowel syndrome treatment market.
According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was projected that the irritable bowel syndrome affects nearly 25-45 million in the U.S. in 2016. Moreover, company advancing the products with symptom precise application and subsequent launches, augment in the geriatric population, and speedy growth in the awareness programs for irritable bowel syndrome treatment are other aspects that contribute toward the growth of the market. Furthermore, effective increase in prevalence of irritable bowel syndrome in female is projected to further boost the growth of worldwide irritable bowel treatment market throughout the forecast period. Therefore, in the near years, it is anticipated that the market of irritable bowel syndrome treatment will increase around the globe more actively over the forthcoming future.
For More Information, refer to below link:-
Ankur Gupta, Head Marketing & Communications